|
Volumn 80, Issue 16, 2013, Pages 1534-1535
|
Clinical/scientific notes
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CARBAMAZEPINE;
MEMBRANE PROTEIN;
PROLINE RICH TRANSMEMBRANE PROTEIN 2;
UNCLASSIFIED DRUG;
ANTICONVULSIVE AGENT;
NERVE PROTEIN;
PRRT2 PROTEIN, HUMAN;
CLINICAL FEATURE;
COHORT ANALYSIS;
DOSE RESPONSE;
DRUG DOSE INCREASE;
DRUG DOSE REDUCTION;
DRUG RESPONSE;
GENE DELETION;
GENETIC ASSOCIATION;
HUMAN;
LOW DRUG DOSE;
MAJOR CLINICAL STUDY;
NOTE;
PAROXYSMAL KINESIGENIC DYSKINESIA;
PRIORITY JOURNAL;
SEQUENCE ANALYSIS;
ARTICLE;
ATHETOSIS;
CHILD;
CHINA;
DISEASE COURSE;
DYSKINESIA;
DYSTONIA;
FEMALE;
GENETICS;
HEMISPHERIC DOMINANCE;
HETEROZYGOTE;
MALE;
MUTATION;
ONSET AGE;
PHENOTYPE;
PHYSIOLOGY;
AGE OF ONSET;
ANTICONVULSANTS;
ATHETOSIS;
CARBAMAZEPINE;
CHILD;
CHINA;
DISEASE PROGRESSION;
DYSKINESIAS;
DYSTONIA;
FEMALE;
FUNCTIONAL LATERALITY;
HETEROZYGOTE;
HUMANS;
MALE;
MEMBRANE PROTEINS;
MUTATION;
NERVE TISSUE PROTEINS;
PHENOTYPE;
MLCS;
MLOWN;
|
EID: 84878759666
PISSN: 00283878
EISSN: 1526632X
Source Type: Journal
DOI: 10.1212/WNL.0b013e31828cf7e1 Document Type: Note |
Times cited : (60)
|
References (7)
|